PHP
KALV

Parkman Healthcare Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Parkman Healthcare Partners’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.9M Buy
1,835,506
+66,998
+4% +$1.08M 3.81% 3
2025
Q4 		$28.6M Buy
1,768,508
+33,505
+2% +$444K 2.72% 7
2025
Q3 		$21.1M Buy
1,735,003
+1,055,940
+155% +$14.6M 2.2% 13
2025
Q2 		$7.68M Sell
679,063
-74,689
-10% -$913K 0.88% 42
2025
Q1 		$8.7M Buy
+753,752
New +$7.69M 1.03% 37

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parkman Healthcare Partners's KALV Position: Q1 2026 in Review

Parkman Healthcare Partners increased its KalVista Pharmaceuticals (KALV) stake by 3.8% in Q1 2026, buying an estimated $1.08M and bringing the position to 1,835,506 shares worth $36.9M. The position accounts for 3.81% of the portfolio, ranked #3.

Parkman Healthcare Partners first reported a position in KALV in Q1 2025 and has held it in 5 quarters since. 184 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Parkman Healthcare Partners held 1,835,506 shares of KalVista Pharmaceuticals worth $36.9M as of Q1 2026.
  • Parkman Healthcare Partners bought 66,998 KalVista Pharmaceuticals shares in Q1 2026, an estimated $1.08M.
  • KalVista Pharmaceuticals made up 3.81% of Parkman Healthcare Partners's portfolio in Q1 2026, its #3 holding.
  • Parkman Healthcare Partners first reported a position in KalVista Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 184 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.